Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Action following the discovery of a global association between the whole genome and adverse event risk in a clinical drug-development programme.

Pharmaceutical statistics - 1 Jan 2000

Whitehead John, Kelly Patrick, Zhou Yinghui, Stallard Nigel, Thygesen Helene, Bowman Clive

Abstract excerpt

Observation of adverse drug reactions during drug development can cause closure of the whole programme. However, if association between the genotype and the risk of an adverse event is discovered, then it might suffice to exclude patients of certain genotypes from future recruitment. Various sequ...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clinical Trials as Topic
Share to Cost of Illness
Share to Drug Discovery

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug-Related Side Effects and Adverse Reactions

Share to Genotype

Share to Models, Statistical

Share to Patient Selection

Share to Risk Assessment

Source

Identifiers

PMID: 19086002
DOI: 10.1002/pst.357

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-19086002-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Action following the discovery of a global association between the whole genome and adverse event risk in a clinical drug-development programme.PMID 19086002Read ↗

Estimation strategies for reacting to the identification of an association between the genome and adverse drug reactions.Semantic proximity Read ↗

Genomics of Adverse Drug Reactions.Semantic proximity Read ↗

Sequential genome-wide association studies for monitoring adverse events in the clinical evaluation of new drugs.Semantic proximity Read ↗

EUDRAGENE: European collaboration to establish a case-control DNA collection for studying the genetic basis of adverse drug reactions.Semantic proximity Read ↗

Potential Role of Pharmacogenomics in Reducing Adverse Drug ReactionsSemantic proximity Read ↗

Genotyping of drug targets: a method to predict adverse drug reactions?Semantic proximity Read ↗

Computational Prediction of Drug Phenotypic Effects Based on Substructure-Phenotype Associations.Semantic proximity Read ↗

A Machine Learning Approach Predicts Tissue-Specific Drug Adverse EventsSemantic proximity Read ↗

DL-ADR: a novel deep learning model for classifying genomic variants into adverse drug reactions.Semantic proximity Read ↗

The phenotype standardization project: improving pharmacogenetic studies of serious adverse drug reactions.Semantic proximity Read ↗

Drug voyager: a computational platform for exploring unintended drug action.Semantic proximity Read ↗

Genome-wide approaches to identify pharmacogenetic contributions to adverse drug reactions.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.